Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-02-02

Clinical Trial Update: A Study of the Safety of Gabapentin in a Potential Over-the-Counter Population With Occasional Sleeplessness [Phase 3]

View source ↗

Summary

Phase 3 study assessing the safety of gabapentin for occasional sleeplessness in a potential OTC population has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Gabapentin (Gabapentin)

Snippet

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Conditions: Transient Insomnia | Phase 3 | Status: COMPLETED